WO2009050461A1 - Diagnostic, predictive and prognostic testing for cancer - Google Patents

Diagnostic, predictive and prognostic testing for cancer Download PDF

Info

Publication number
WO2009050461A1
WO2009050461A1 PCT/GB2008/003501 GB2008003501W WO2009050461A1 WO 2009050461 A1 WO2009050461 A1 WO 2009050461A1 GB 2008003501 W GB2008003501 W GB 2008003501W WO 2009050461 A1 WO2009050461 A1 WO 2009050461A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
biomarker
level
subject
aurora
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/003501
Other languages
English (en)
French (fr)
Inventor
Kai Stoeber
Gareth Hayden Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Cancer Diagnostics Ltd
Original Assignee
Cambridge Cancer Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2008801209233A priority Critical patent/CN101896819A/zh
Priority to JP2010529444A priority patent/JP5559056B2/ja
Priority to ES08840139T priority patent/ES2395890T3/es
Priority to US12/738,062 priority patent/US8512716B2/en
Priority to EP08840139A priority patent/EP2208070B1/en
Priority to CA2702653A priority patent/CA2702653A1/en
Application filed by Cambridge Cancer Diagnostics Ltd filed Critical Cambridge Cancer Diagnostics Ltd
Priority to AU2008313459A priority patent/AU2008313459B2/en
Priority to DK08840139.3T priority patent/DK2208070T3/da
Publication of WO2009050461A1 publication Critical patent/WO2009050461A1/en
Anticipated expiration legal-status Critical
Priority to US13/873,487 priority patent/US20140154680A1/en
Priority to US15/141,908 priority patent/US20180223366A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Definitions

  • Cells are responsive to mitogens in their environment at a discrete time in G1 , referred to as the restriction point. The absence of mitogens does not affect cell cycle progression through S, G2 and M phase until cells return to their sensitive window in G1.
  • cells accumulate with a 2N DNA content and exit into GO.
  • the cell cycle phase transitions are driven by changes in cyclin-CDK pairs. Cyclin D-CDK4, cyclin D- CDK6 and cyclin E-CDK2 regulate G0/G1 and are required for full E2F activity, S phase is initiated by cyclinA-CDK2, and cyclin B-CDK1 regulates progression through G2 and entry into mitosis. What distinguishes cells in out-of-cycle states from cells engaged in cycle remains to be elucidated.
  • the present invention provides a method of predicting response to therapy or predicting disease progression in a cancer, the method comprising determining the presence or absence of abnormally proliferating cells or cellular growth abnormality in a body sample from an individual, the method including detecting in the sample a target polypeptide, wherein the target polypeptide is selected from group consisting of DNA replication licensing factors, Aurora kinases, Ki67, geminin, Polo-like kinases,

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/GB2008/003501 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer Ceased WO2009050461A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2008313459A AU2008313459B2 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer
JP2010529444A JP5559056B2 (ja) 2007-10-15 2008-10-15 ガンの診断、予測、および予後試験
ES08840139T ES2395890T3 (es) 2007-10-15 2008-10-15 Ensayo de diagnóstico, predictivo y de prognosis para el cáncer
US12/738,062 US8512716B2 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer
EP08840139A EP2208070B1 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer
CN2008801209233A CN101896819A (zh) 2007-10-15 2008-10-15 对癌症的诊断测试、预测测试和预后测试
DK08840139.3T DK2208070T3 (da) 2007-10-15 2008-10-15 Diagnostisk prædiktiv og prognostisk test for cancer
CA2702653A CA2702653A1 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer
US13/873,487 US20140154680A1 (en) 2007-10-15 2013-04-30 Diagnostic, predictive and prognostic testing for cancer
US15/141,908 US20180223366A1 (en) 2007-10-15 2016-04-29 Diagnostic, predictive and prognostic testing for cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0720113.0A GB0720113D0 (en) 2007-10-15 2007-10-15 Diagnostic, prognostic and predictive testing for cancer
GB0720113.0 2007-10-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/738,062 A-371-Of-International US8512716B2 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer
US13/873,487 Continuation US20140154680A1 (en) 2007-10-15 2013-04-30 Diagnostic, predictive and prognostic testing for cancer

Publications (1)

Publication Number Publication Date
WO2009050461A1 true WO2009050461A1 (en) 2009-04-23

Family

ID=38813827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003501 Ceased WO2009050461A1 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer

Country Status (11)

Country Link
US (3) US8512716B2 (enExample)
EP (1) EP2208070B1 (enExample)
JP (2) JP5559056B2 (enExample)
CN (1) CN101896819A (enExample)
AU (1) AU2008313459B2 (enExample)
CA (1) CA2702653A1 (enExample)
DK (1) DK2208070T3 (enExample)
ES (1) ES2395890T3 (enExample)
GB (1) GB0720113D0 (enExample)
PT (1) PT2208070E (enExample)
WO (1) WO2009050461A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073619A1 (en) * 2009-12-15 2011-06-23 Cytosystems Limited Assay
CN110846405A (zh) * 2010-07-23 2020-02-28 哈佛大学校长及研究员协会 用于检测体液中的疾病或病症标记的方法
US11391744B2 (en) 2015-06-08 2022-07-19 Arquer Diagnostic Limited Methods and kits
US11519916B2 (en) 2015-06-08 2022-12-06 Arquer Diagnostics Limited Methods for analysing a urine sample
RU2842725C2 (ru) * 2023-10-17 2025-07-01 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Способ определения вероятности рецидивов колоректального рака

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105324670B (zh) * 2013-05-09 2018-08-03 宝洁公司 用于评估健康状况的方法和系统
CN103592444A (zh) * 2013-11-27 2014-02-19 中国人民解放军沈阳军区总医院 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法
US9857354B2 (en) 2014-06-01 2018-01-02 Novazoi Theranostics, Inc. Compositions and methods for prognosis and treatment of neoplasm
CN114717312B (zh) * 2015-02-17 2024-04-26 浙江数问生物技术有限公司 用于膀胱癌分子亚型分型的方法和试剂盒
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN108344868B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人早期胚胎的发育分期中的应用
CN108344867B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人卵母细胞成熟分期中的应用
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN109988708B (zh) * 2019-02-01 2022-12-09 碳逻辑生物科技(中山)有限公司 一种用于对患有结肠直肠癌的患者进行分型的系统
CN110846413B (zh) * 2019-11-23 2023-05-26 中南大学湘雅三医院 Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
JP2025507447A (ja) * 2022-02-01 2025-03-18 ４ディー・パス・インコーポレイテッド 画像に基づく疾患特性評価のためのシステム及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146513A1 (en) 1999-04-01 2004-07-29 Dakocytomation Denmark A/S Monoclonal antibodies against human protein Mcm3, process for their production, and their use
US20070128599A1 (en) 2002-10-28 2007-06-07 Ruediger Ridder Method for improved diagnosis of dysplasias

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
CA2848463A1 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005108615A2 (en) * 2004-04-14 2005-11-17 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
AU2005289728B2 (en) * 2004-09-22 2011-11-24 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
US20080145358A1 (en) * 2005-02-18 2008-06-19 Astrazeneca Ab Method for Determining Responsiveness to Chk1 Inhibitors
US8399442B2 (en) * 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
EP1977246B1 (en) * 2005-12-30 2010-01-20 Ventana Medical Systems, Inc. Na+, k+-atpase expression in cervical dysplasia and cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146513A1 (en) 1999-04-01 2004-07-29 Dakocytomation Denmark A/S Monoclonal antibodies against human protein Mcm3, process for their production, and their use
US20070128599A1 (en) 2002-10-28 2007-06-07 Ruediger Ridder Method for improved diagnosis of dysplasias

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
ANANTHANARAYANAN ET AL., BMC CANCER, vol. 6, no. 73, 2006, pages 1 - 9
ANANTHANARAYANAN VIJAYALAKSHMI ET AL: "Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 17 March 2006 (2006-03-17), pages 73, XP021016277, ISSN: 1471-2407 *
BARKLEY ET AL., EXP CELL RES, vol. 313, 2007, pages 3789 - 3799
BLOW; HODGSON, TRENDS CELL BIOL, vol. 12, 2002, pages 72 - 78
DUDDERIDGE ET AL., CLIN CANCER RES, vol. 11, 2005, pages 2510 - 7
DUDDERIDGE ET AL., CLIN CANCER RES, vol. 11, 2005, pages 25110 - 2517
DUNKLER ET AL., EUR J CANCER, vol. 43, 2007, pages 745 - 751
ENDL E ET AL: "The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells", JOURNAL OF PATHOLOGY 2001 GB, vol. 195, no. 4, 2001, pages 457 - 462, XP002506508, ISSN: 0022-3417 *
ENDL, JOURNAL OF PATHOLOGY, vol. 195, 2001, pages 457 - 452
EWARD ET AL., J CELL SCI, vol. 117, 2004, pages 5875 - 5886
GOING ET AL., GUT, vol. 50, 2002, pages 373 - 377
GOING J J ET AL: "Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa", GUT, BRITISH MEDICAL ASSOCIATION, LONDON, vol. 50, no. 3, 1 March 2002 (2002-03-01), pages 373 - 377, XP002406753, ISSN: 0017-5749 *
GONZALEZ ET AL., J PATHOL, vol. 204, 2004, pages 121 - 130
GRITSKO ET AL., CLIN CANCER RES, vol. 9, 2003, pages 1420 - 6
HAROSKE ET AL., ANAL CELL PATHOL 1998, vol. 17, 1997, pages 189 - 200
HAROSKE ET AL., ANAL CELL PATHOL, vol. 17, 1997, pages 189 - 200
KINGSBURY ET AL., EXP CELL RES, vol. 309, 2005, pages 56 - 67
KORKOLOPOULOU ET AL., HUMAN PATHOLOGY, vol. 36, 2005, pages 899 - 907
KORKOLOPOULOU ET AL: "Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators", HUMAN PATHOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 36, no. 8, 1 August 2005 (2005-08-01), pages 899 - 907, XP005012618, ISSN: 0046-8177 *
KRUDE ET AL., CELL, vol. 88, 1997, pages 109 - 19
LI ET AL., MOLECULAR CANCER, vol. 6, no. 7, 2007, pages 1 - 17
LI Y ET AL: "Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized", MOLECULAR CANCER 2007 GB, vol. 6, 18 January 2007 (2007-01-18), XP002506506, ISSN: 1476-4598 *
PADMANABHAN ET AL., J. CLIN. PATHOL., vol. 57, 2004, pages 1057 - 1062
PADMANABHAN V ET AL: "DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer.", JOURNAL OF CLINICAL PATHOLOGY OCT 2004, vol. 57, no. 10, October 2004 (2004-10-01), pages 1057 - 1062, XP002506509, ISSN: 0021-9746 *
SCOTT ET AL., BRITISH JOURNAL OF CANCER, vol. 90, 2004, pages 1583 - 1590
SCOTT I S ET AL: "A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: Implications for the histopathological assessment of paraffin-embedded specimens", BRITISH JOURNAL OF CANCER 20040419 GB, vol. 90, no. 8, 19 April 2004 (2004-04-19), pages 1583 - 1590, XP002506507, ISSN: 0007-0920 *
SHETTY A ET AL: "DNA replication licensing and cell cycle kinetics of normal and neoplastic breast", BRITISH JOURNAL OF CANCER 20051128 GB, vol. 93, no. 11, 28 November 2005 (2005-11-28), pages 1295 - 1300, XP002506505, ISSN: 0007-0920 1532-1827 *
SHETTY ET AL., BR J CANCER, vol. 93, 2005, pages 1295 - 1300
SHETTY ET AL., BR J CANCER, vol. 93, 2005, pages 1295 - 300
SHETTY ET AL., BRITISH JOURNAL OF CANCER, vol. 93, no. 11, 2005, pages 1295 - 1300
STOEBER ET AL., CELL, vol. 114, 2001, pages 2027 - 2041
STOEBER ET AL., EMBO J, vol. 17, 1998, pages 7219 - 7229
STOEBER ET AL., J CELL SCI, vol. 114, 2001, pages 2027 - 2041
STOEBER ET AL., J CELL SCI, vol. 114, 2001, pages 2027 - 41
SUDBO ET AL., N ENGL J MED, vol. 344, 2001, pages 1270 - 8
TRIMBOS JB ET AL., J NATL CANCER INST, vol. 95, 2003, pages 105 - 12
VEGOTE I ET AL., CURR. OP. ONCOL., vol. 15, 2003, pages 452 - 5
WHARTON ET AL., BR J CANCER, vol. 91, 2004, pages 262 - 9
WHARTON SB; HIBBERD S; EWARD KL ET AL., BR J CANCER, vol. 91, 2004, pages 262 - 9
WILLIAMS; STOEBER, CURR OPIN CELL BIOL, vol. 19, 2007, pages 672 - 679
YANG ET AL., BMC CANCER, vol. 6, 2006, pages 203
YANG JUN ET AL: "Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.", BMC CANCER 2006, vol. 6, 2006, pages 203, XP002506510, ISSN: 1471-2407 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073619A1 (en) * 2009-12-15 2011-06-23 Cytosystems Limited Assay
CN102782497A (zh) * 2009-12-15 2012-11-14 赛托系统有限公司 测定
EP2977762A3 (en) * 2009-12-15 2016-05-04 Cytosystems Limited Assay
US10267801B2 (en) 2009-12-15 2019-04-23 Cytosystems Limited Assay
CN110846405A (zh) * 2010-07-23 2020-02-28 哈佛大学校长及研究员协会 用于检测体液中的疾病或病症标记的方法
US11391744B2 (en) 2015-06-08 2022-07-19 Arquer Diagnostic Limited Methods and kits
US11519916B2 (en) 2015-06-08 2022-12-06 Arquer Diagnostics Limited Methods for analysing a urine sample
RU2842725C2 (ru) * 2023-10-17 2025-07-01 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Способ определения вероятности рецидивов колоректального рака

Also Published As

Publication number Publication date
US20140154680A1 (en) 2014-06-05
JP5559056B2 (ja) 2014-07-23
CA2702653A1 (en) 2009-04-23
EP2208070B1 (en) 2012-10-03
AU2008313459A1 (en) 2009-04-23
JP5837630B2 (ja) 2015-12-24
GB0720113D0 (en) 2007-11-28
PT2208070E (pt) 2013-01-08
US20180223366A1 (en) 2018-08-09
US20100285474A1 (en) 2010-11-11
DK2208070T3 (da) 2012-12-17
EP2208070A1 (en) 2010-07-21
CN101896819A (zh) 2010-11-24
US8512716B2 (en) 2013-08-20
JP2011501809A (ja) 2011-01-13
ES2395890T3 (es) 2013-02-15
AU2008313459B2 (en) 2013-01-24
JP2014095726A (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
AU2008313459B2 (en) Diagnostic, predictive and prognostic testing for cancer
Vischioni et al. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer
Bodner-Adler et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis
Wei et al. Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance
Heckl et al. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium
Nishimura et al. Evaluation of factors related to late recurrence-later than 10 years after the initial treatment-in primary breast cancer
Zhang et al. eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation
Schindlbeck et al. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIα, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow
US20120245051A1 (en) Objective, quantitative method to predict histological subtype in non-small cell lung cancer
Li et al. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
Pierssens et al. Chromosome instability in tumor resection margins of primary OSCC is a predictor of local recurrence
Chen et al. The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma
JP4848355B2 (ja) 臨床診療における新規増殖マーカーおよび癌の予後または診断のためのそれらの用途
Wu et al. Combining the tyrosine kinase inhibitor cabozantinib and the mTORC1/2 inhibitor sapanisertib blocks ERK pathway activity and suppresses tumor growth in renal cell carcinoma
GB2519830A (en) Methods for monitoring treatment response and relapse in ovarian cancer
Byrne et al. BRCA1 and MAD2 are coexpressed and are prognostic indicators in tubo-ovarian high-grade serous carcinoma
Evans et al. Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels
Liu et al. Expression of p53, p16 and cyclooxygenase‐2 in esophageal cancer with tissue microarray
Schindlbeck et al. Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
US8609354B2 (en) Method for selecting patients for treatment with an EGFR inhibitor
JP2009524048A (ja) Ｓｈｃタンパク質を使用して消化管および他の癌の再発の予後を診断するための方法
Kamal et al. Prognostic outcome of mesenchymal transition biomarkers in correlation with EGFR expression in epithelial ovarian carcinoma patients
Liu et al. Targeting PIK3CB/YAP1 improves the sensitivity of paclitaxel by suppressing aging in head and neck squamous tumor cells
Brucka et al. Immunohistochemical pattern of protein P21, cyclin D1 and cyclin E in endometrial hyperplasia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880120923.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08840139

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008313459

Country of ref document: AU

Ref document number: 2702653

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010529444

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008840139

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008313459

Country of ref document: AU

Date of ref document: 20081015

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12738062

Country of ref document: US